本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, May 12, 2023 /PRNewswire/ -- Yadea (01585.HK), a global leading brand of developing and manufacturing two-wheeler electric vehicles, won four international product design awards, namely two Red Dot Awards and two iF DESIGN AWARDs. After winning IDEA awards in 2022, Yadea became a winner brand again. The winners are Yadea E-motorcycle KEENESS, Yadea S9 and Yadea Scooter ElitePrime. These three new e-mobility products stood out among many entries with their advanced aesthetic design, excellent user experience and environmental protection concept. The Red Dot Award is a German award that recognizes products with outstanding design and high industry impact. The iF DESIGN AWARD is recognized as an arbiter of excellent design and is one of the most important design awards in the world. Yadea KEENESS is equipped with a 10kW mid-drive motor, with a top speed of 100km/h and an acceleration of 0-50km/h in 4 seconds. The battery is equipped with a smart energy retrieving system to enhance power and extend the battery life, and once charge can run more than 100km. As the 2023 hero product, the Yadea ElitePrime is a powerful, safe and foldable SUV-like e-scooter with high performance, allowing you to conquer all road conditions. Yadea ElitePrime equipped with a motor with a peak power of 1500W. And it can achieve 30% climbing gradients and has a excellent front and rear shock absorption structure. Meanwhile, Yadea announced its global launch through the Indiegogo crowdfunding with its super early bird price last month. Yadea S9 is an e-bike with super long battery life and can easily drive more than 150km. It uses the TTFAR carbon fiber 2.0 lithium battery first created by Yadea. This battery uses square laminated cells and compact PACK technology, and its capacity is 100% higher than ordinary lithium battery. In addition, the motor rated power of Yadea S9 can reach 1000W, which has a strong starting acceleration capability. Yadea's products range mainly covering high-performance electric motorcycles, electric mopeds, electric bicycles, and electric kick scooters. Yadea has provided e-mobility products and services to 70 million users in over 100 countries and regions and built a network of 40,000+ retailers worldwide. For more information, please visit theOfficial Website: https://www.yadea.com/
SINGAPORE, May 12, 2023 /PRNewswire/ -- As a leading cryptocurrency exchange, BingX is committed to providing its users with fast, secure, and innovative trading services. In its latest effort to further develop its spot trading capabilities, BingX has announced the integration of zkSync Era to support online crypto deposit and withdrawal. BingX Expands Spot Trading with zkSync Era Integration and Launched BRC-20 Zone zkSync Era is a Layer-2 protocol that scales Ethereum with cutting-edge ZK tech. zkSync uses zero-knowledge proofs (zk-proofs) to enable fast and cheap transactions. With zkSync, users can deposit and withdraw funds to and from the main Ethereum network in a faster and easier way, without having to wait for long confirmation times or pay high gas fees. BingX's integration with zkSync Era enhances the spot trading experience. Without registering a separate private key, users are able to do secure and near-instant online deposits and withdrawals of cryptocurrencies. BingX has announced that CHEEMS USDT is now available for trading on its platform. "The integration of zkSync Era and support of BRC20 tokens are part of our continuous efforts to enhance our spot trading services and support the growth of the blockchain industry," said Elvisco Carrington, PR and Communications Director of BingX. "We are thrilled to offer our users a more streamlined and cost-effective way to conduct spot trading over a wider range of cryptocurrencies and tokens. As part of our ongoing commitment to offering access to the most promising and innovative projects in this ecosystem, BingX looks forward to providing a better trading experience for users and continuing our role as a leading innovator." About BingX BingX is a leading crypto exchange that offers spot, derivatives, copy, and grid trading services to over 100 countries and regions worldwide with over 5 million users. BingX continues to connect users with expert traders and the platform in a safe and innovative way.
NEW YORK and GEORGE TOWN, Cayman Islands, May 12, 2023 /PRNewswire/ -- Capitalworks Emerging Markets Acquisition Corp. ("CEMAC") (NASDAQ: CMCA), a publicly traded special purpose acquisition company organized in the Cayman Islands to effect a merger, stock exchange, asset acquisition, stock purchase, recapitalization or other similar business combination, announced an update on its previously announced initial business combination with Lexasure Financial Group ("Lexasure" or the "Company"), pursuant to which a new Cayman Islands holdings company, Lexasure Financial Holdings Corp. ("Pubco"), will acquire both Lexasure and CEMAC. CEMAC is seeking shareholder approval for a nine-month extension to March 3, 2024, of its deadline to complete a business combination at a shareholder meeting scheduled for May 23, 2023. Lexasure provides reinsurance and digital insurance solutions, including Reinsurance-as-a-Service (RaaS), to the growing markets of Southeast and South Asia. The Company seeks to enable local direct insurers to compete across emerging Asian markets through innovative product solutions designed to empower insurers, companies, and individuals to manage risk more effectively and accelerate their growth. These product solutions include Lexasure's recently launched comprehensive mobile apps, Vivacity and Flourish, which are designed to promote healthy lifestyles, improve engagement for health insurance providers, and provide farmers with insurance coverage and mobile technology in the event of the failure of crops and livestock, respectively. In its traditional lines of business, Lexasure underwrites reinsurance and insurance and serves as a broker for a diverse set of industries, working with over 60 primary insurers across 22 countries in Asia, the Middle East, and North America. Lexasure is led by a senior leadership team comprised of insurance veterans and technology leaders with over 150 years of combined industry experience. Lexasure's Chairman, Richard Goh, has over 40 years of experience in the insurance business and is the former CEO of a Labuan composite insurance group that has operations in Indonesia, the Philippines, and Malaysia. Lexasure's founder and CEO, Ian Lim, has over 25 years of experience in the reinsurance and insurance industries, having previously served in senior leadership roles at BMS Asia and SiriusPoint. Additional information on Lexasure is provided in an investor presentation available on their investor relations website at https://ir.lexasure.com by clicking on the Events & Presentations page under the News & Events heading. Important Information About the Proposed Transaction and Where to Find It The proposed business combination will be submitted to the shareholders of CEMAC for their consideration and approval. Pubco intends to file a registration statement on Form F-4 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC"), which will include preliminary and definitive proxy statements to be distributed to CEMAC's shareholders in connection with CEMAC's solicitation for proxies for the vote by CEMAC's shareholders in connection with the proposed business combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued by Pubco to Lexasure's shareholders and CEMAC's securityholders in connection with the completion of the proposed business combination. After the Registration Statement has been filed and declared effective, CEMAC will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the proposed business combination. CEMAC's shareholders and other interested persons are advised to read, once available, the Registration Statement and the preliminary proxy statement/prospectus and any amendments thereto and, once available, the definitive proxy statement/prospectus in connection with CEMAC's solicitation of proxies for its special meeting of shareholders to be held to approve, among other things, the proposed business combination, because these documents will contain important information about CEMAC, Lexasure, Pubco and the proposed business combination. CEMAC shareholders and other interested parties may also obtain a copy of the Registration Statement and the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC regarding the proposed business combination and other documents filed with the SEC by CEMAC, without charge, at the SEC's website located at www.sec.gov or by directing a request to Capitalworks Emerging Markets Acquisition Corp., 1345 Avenue of the Americas, 11th Floor, New York, NY, 10105, USA. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY, NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE PROPOSED TRANSACTION PURSUANT TO WHICH ANY SECURITIES ARE TO BE OFFERED OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Lexasure's, Pubco's and CEMAC's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Lexasure, Pubco and CEMAC. These forward-looking statements are subject to a number of risks and uncertainties, including the occurrence of any event, change or other circumstances that could give rise to the termination of the proposed business combination; the outcome of any legal proceedings that may be instituted against Lexasure, Pubco or CEMAC or others following the announcement of the proposed business combination; the inability to complete the proposed business combination due to the failure to obtain approval of the shareholders of Lexasure or CEMAC or to satisfy other conditions to closing; changes to the proposed structure of the proposed business combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the proposed business combination; the ability to meet stock exchange listing standards following the consummation of the proposed business combination; the risk that the proposed business combination disrupts current plans and operations of Lexasure as a result of the announcement and consummation of the proposed business combination; the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition and the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and retain its management and key employees; costs related to the proposed business combination; changes in applicable laws or regulations; Lexasure's estimates of expenses and profitability and underlying assumptions with respect to shareholder redemptions and purchase price and other adjustments; any downturn or volatility in economic conditions; the effects of COVID-19 or other epidemics; changes in the competitive environment affecting Lexasure or its customers, including Lexasure's inability to introduce new products or technologies; the impact of pricing pressure and erosion; supply chain risks; risks to Lexasure's ability to protect its intellectual property and avoid infringement by others, or claims of infringement against Lexasure; the possibility that Lexasure, Pubco or CEMAC may be adversely affected by other economic, business and/or competitive factors; Lexasure's estimates of its financial performance; risks related to the fact that each of Lexasure and Pubco is incorporated in the Cayman Islands and governed by Cayman Islands law; and those factors discussed in CEMAC's final prospectus dated November 30, 2021, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, in each case, under the heading "Risk Factors," and other documents of CEMAC or Pubco filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that none of Lexasure, Pubco or CEMAC presently knows or that Lexasure, Pubco and CEMAC currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Lexasure's, Pubco's and CEMAC's expectations, plans, or forecasts of future events and views as of the date of this press release. Lexasure, Pubco and CEMAC anticipate that subsequent events and developments will cause Lexasure's, Pubco's and CEMAC's assessments to change. However, while Lexasure, Pubco and CEMAC may elect to update these forward-looking statements at some point in the future, Lexasure, Pubco and CEMAC specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Lexasure's, Pubco's and CEMAC's assessments as of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. No Offer or Solicitation This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Participants in Solicitation CEMAC, Lexasure, Pubco and certain of their respective directors, executive officers, and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from CEMAC's shareholders in connection with the proposed business combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of CEMAC's shareholders in connection with the proposed business combination will be set forth in CEMAC's proxy statement/prospectus when it is filed with the SEC. You can find more information about CEMAC's directors and executive officers in CEMAC's final prospectus dated November 30, 2021. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors, and other interested persons should read the proxy statement / prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above. Investor and Media Contacts: Crocker Coulson, CEO, AUM Media+1 (646) 652-7185crocker.coulson@aummedia.org Cody Slach+1 (949) 574-3860CMCA@gatewayir.com
CHANGSHA, China, May 12, 2023 PRNewswire/-- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") is hosting a technological achievements exhibition themed "Technology Salute to the New Era" from May 11 to 14 in the Zoomlion Smart Industrial City (the "City") in Changsha, Hunan Province, showcasing its achievements in intelligent manufacturing, intelligent product development, and digital transformation. The event is also the first time the City has opened its doors to the public. Technological Innovations Drive Product Breakthroughs The exhibition showcases Zoomlion's achievements and milestones in product development across multiple sectors. Zoomlion has adhered to the "Deep Root in Technology with Product as the Center" principle to create products carrying forward technological innovations in construction machinery, agricultural equipment, and new construction materials. Zoomlion has leveraged cutting-edge technologies including 5G, big data, industrial internet, AI, and blockchain to tackle the technological bottlenecks of construction machinery intelligent manufacturing. Zoomlion has achieved continuous breakthroughs with record-breaking products. It has launched the world's largest 20,000 ton-meter tower crane, the 2,400-ton all-terrain crane with the world's largest hosting capability, the tallest 68-meter aerial work platform, and the world's first excavators and cranes with 5G remote control. A smart City boasting world-class intelligent manufacturing capabilities The City, the world's largest construction machinery industry base in terms of both scale and product lineup, is home to eight world-leading lighthouse factories, 300 intelligent production lines, and eight national tech innovation platforms, boasting more than 150 industry-leading technologies and over 600 patented production technologies. The Earthmoving Machinery Smart Park has the industry's most intelligent smart factory with 61 intelligent production lines, four of which are "lights-out" lines (meaning there is no human involvement). Upon completion, the smart park will reduce the R&D cycle by 30 percent, improve production efficiency by 25 percent, and lower per-unit energy consumption by 12 percent. It will be able to produce an excavator every six minutes on average, boasting an annual production capacity of 50,000 units. The City has also set up a world-class hoisting machinery park that aims to achieve 100 percent real-time data collection of intelligent equipment and IT-networked production lines, rolling off one crane in 18 minutes and reducing the delivery period by 32 percent. It will also produce the world's most intelligent manufacturing base of aerial working platforms which leverages more than 60 patented production line, and 12 innovative, technologies to shorten product delivery time by 55 percent, producing a scissor-type product every 7.5 minutes and boom-type product every 20 minutes. Additionally, there is an industry-leading concrete pumping machinery smart park that adopts visual identity, AI decision-making, laser scanning, and 3D modeling technologies to achieve a 90 percent automation rate of core production processes, producing a pump truck every 30 minutes. Zoomlion signed orders totaling 4.691 billion yuan ($675.33 million) on the Exhibition's opening day. "We are grateful for the tremendous innovations in science and technology in this new era, as well as the support and encouragement from our leadership, trust and inclusiveness from our global customers, suppliers, and competitors from both home and abroad. We appreciate the support and attention given to innovation from our shareholders, investors, and media friends. We also recognize the contributions of our staff to this innovation. With confidence, Zoomlion will continue to lead the new revolution of technology, reaching new heights and broadening our horizons to drive innovation and transformation in the construction machinery industry," said Zhan Chunxin, CEO of Zoomlion. Machine cluster collaboration in Zoomlion Smart Industrial City Zoomlion displays product breakthroughs driven by technological innovations Zoomlion's factory in Changsha Smart Industrial City
重慶2023年5月12日 /美通社/ -- 5月8日下午，長安汽車2022年度業績說明會舉行。在說明會上，長安汽車公佈了2022年度業績，並且就該公司的未來發展，進行了規劃和戰略展望。 長安汽車的2022年銷量達到234.6萬輛，較上年增長2%，達到五年來新高。在2022年銷量中，新能源汽車銷量較上年增長160.5%，達到284,000輛。長安汽車2022年歸屬於股東的淨利潤為77.98億元人民幣，較上年增長119.52%，運營品質呈現出持續增長勢頭，價值創造能力也呈現向上趨勢。長安汽車成功地在銷量和利潤上面，取得了良好業績。 展望未來，長安汽車將會加速新能源汽車的開發，進行國際擴展，堅定地轉型成為一家智能低碳出行科技公司。現在，長安汽車發佈名為「海納百川計劃」的海外戰略，該計劃將會通過加速「五大佈局」，來推動海外發展。這包括在歐洲、美洲、中東和非洲、亞太、獨聯體五大地區加速佈局，實現「一區一策、一國一策」，到2025年推出不少於30款全球產品。海納百川計劃將要讓海外市場網點突破3,000家。長安汽車計劃到2030年，實現「四個一」目標：海外投資突破100億美元、年海外銷量超過120萬輛、海外企業員工數量超過10,000人、成為世界一流的汽車品牌。
GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID. "This news acknowledges the need to maintain access to a diverse COVID vaccine portfolio," said John C. Jacobs, President and Chief Executive Officer, Novavax. "We are pleased with this adolescent authorization in Singapore as it ensures a protein-based option as part of public health measures." Extended interim authorization was based on data from the pediatric expansion of the Phase 3 PREVENT-19 trial of 1,799 adolescents aged 12 through 17 years in the U.S., to evaluate the safety and effectiveness of Nuvaxovid. In the trial, Nuvaxovid achieved its primary endpoint based on neutralising antibody response and demonstrated clinical efficacy overall at a time when the Delta variant was the predominant circulating SARS-CoV-2 strain in the U.S. Novavax's vaccine is authorized for use in more than 40 markets around the world. In Singapore, the HSA previously granted interim authorization for Nuvaxovid to prevent COVID-19 in adults aged 18 and older in February 2022. Trade Name in the U.S. The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration (FDA). Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S. The Novavax COVID-19 Vaccine, Adjuvanted vaccine has not been approved or licensed by the U.S. FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) as a primary series in individuals 12 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted vaccine is also authorized to provide a first booster dose at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Authorized Use The Novavax COVID-19 Vaccine, Adjuvanted is authorized for use under an Emergency Use Authorization (EUA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted vaccine is also authorized to provide a first booster dose at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine. IMPORTANT SAFETY INFORMATION Contraindications Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted. Warnings and Precautions Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Novavax COVID-19 Vaccine, Adjuvanted. Monitor the Novavax COVID-19 Vaccine, Adjuvanted recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control (CDC) and Prevention guidelines. Myocarditis and Pericarditis: Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of the Novavax COVID-19 Vaccine, Adjuvanted (see Full EUA Prescribing Information). The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis). Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting. Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted. Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients. Adverse Reactions Adverse reactions reported in clinical trials following administration of the Novavax COVID-19 Vaccine, Adjuvanted include injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling, fever, chills, injection site pruritus, hypersensitivity reactions, lymphadenopathy-related reactions, myocarditis, and pericarditis. Myocarditis, pericarditis, anaphylaxis, paresthesia, and hypoesthesia have been reported following administration of the Novavax COVID-19 Vaccine, Adjuvanted outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Novavax COVID-19 Vaccine, Adjuvanted. Reporting Adverse Events and Vaccine Administration ErrorsThe vaccination provider enrolled in the federal COVID-19 Vaccination Program is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): vaccine administration errors whether or not associated with an adverse event, serious adverse events (irrespective of attribution to vaccination), cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS), in adults and children, and cases of COVID-19 that results in hospitalization or death. Complete and submit reports to VAERS online: For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words "Novavax COVID-19 Vaccine, Adjuvanted EUA" in the description section of the report. To the extent feasible, report adverse events to Novavax, Inc. using the following contact information or by providing a copy of the VAERS form to Novavax, Inc. Website: www.NovavaxMedInfo.com, Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829). Please click to see the Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and EUA Full Prescribing Information. Please click to see the Fact Sheet for Recipients and Caregivers. About Nuvaxovid™ (NVX-CoV2373) NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID. With Novavax's unique recombinant nanoparticle technology, the non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax's Matrix-M™ adjuvant enhances and broadens the immune response. The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2° to 8°C, enabling the use of existing vaccine supply and cold chain channels. About the PREVENT-19 Phase 3 Trial The PRE-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19 (PREVENT-19) was a randomized, placebo-controlled, observer-blinded Phase 3 trial conducted in the U.S. and Mexico to evaluate the efficacy and safety of NVX-CoV2373 as a primary series and as a booster in adults and adolescents to prevent SARS-CoV-2 infection. As a primary series, the primary endpoint was the first occurrence of polymerase chain reaction (PCR)-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least seven days after the second dose in 29,960 adult participants aged 18 and older at baseline without protocol violations prior to illness. A secondary endpoint was the prevention of PCR-confirmed, symptomatic moderate or severe COVID-19. Full results of the trial were published in the New England Journal of Medicine. The pediatric expansion of the trial evaluated 2,247 adolescents aged 12 through 17 years in the U.S. Results from the expansion were announced in February 2022. About Matrix-M™ Adjuvant When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enhances the immune system response, making it broader, and more durable. The Matrix-M adjuvant stimulates the entry of antigen-presenting cells at the injection site and enhances antigen presentation in local lymph nodes. About Novavax Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing, and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, the timing of clinical trial results, the ongoing development of NVX-CoV2373, NVX-CoV2515 and bivalent Omicron-based / original strain based vaccine, a COVID-19-Influenza Combination investigational vaccine candidate, a quadrivalent influenza investigational vaccine candidate, the scope, timing and outcome of future regulatory filings and actions, including Novavax's plans to supplement existing authorizations with data from the additional manufacturing sites in Novavax's global supply chain, additional worldwide authorizations of NVX-CoV2373 for use in adults and adolescents, and as a booster, the evolving COVID-19 pandemic, the potential impact and reach of Novavax and NVX-CoV2373 in addressing vaccine access, controlling the pandemic and protecting populations, the efficacy, safety intended utilization, and the expected administration of NVX-CoV2373 are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: Investors Erika Schultz 240-268-2022 ir@novavax.com MediaAli Chartan 240-720-7804 media@novavax.com
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
